Seamless Therapeutics, a Dresden, Germany-based biotechnology company providing a recombinase platform, raised $12.5M in Seed funding.
The round was led by Wellington Partners and Forbion, with non-dilutive funding from BMBF GO-Bio. Representatives from both Wellington and Forbion will join the company’s newly formed board of directors.The company intends to use the funds to further advance its proprietary technology platform to build a pipeline of therapeutic candidates towards first-in-human readiness as well as to expand the presence in the EU & US.Led by CEO Anne-K. Heninger, and CSO Felix Lansing, Seamless Therapeutics is applying its proprietary know-how to develop a pipeline of disease-modifying product candidates across a broad spectrum of indications to expand the therapeutic potential of gene editing. The platform has succeeded in reprogramming site specific recombinases to any given target sequence and make a range of specific changes including inversion, excision, exchange, and insertion from small to larger DNA fragments. Recombinases are a class of enzymes that have been widely used in scientific research for decades to precisely modify the genome of model organisms but until now could not be applied as a therapeutic due to their limited programmability to act on new target sites.16/03/2023
